Our iGEM project, focusing on innovative treatment for hepatic encephalopathy (HE), has identified key stakeholders critical to the success and real-world application of our research. These stakeholders include HE patients, medical professionals (doctors), pharmaceutical company representatives, research experts involved in HE-related studies, and the general public.
Patients: Suffering from HE represent a primary stakeholder, as their quality of life directly depends on effective treatment options.
Doctors: Especially hepatologists and neurologists, are integral in diagnosing and treating HE, providing us with valuable insights into clinical needs.
Pharmaceutical company representatives: They are vital for translating research into market-ready therapies, ensuring accessibility and scalability of our solutions.
Researchers: Including academics and specialists in liver disease, are critical for guiding the scientific direction of the project.
General public: As raising awareness and educating people about HE can significantly contribute to early diagnosis and treatment, ultimately benefiting the healthcare ecosystem as a whole.</p>